BACKGROUND: Information is limited regarding the rates of progression to congestive heart failure (CHF) and death in individuals with asymptomatic left ventricular systolic dysfunction (ALVD). We sought to characterize the natural history of ALVD, by studying unselected individuals with this condition in the community. METHODS AND RESULTS: We studied 4257 participants (1860 men) from the Framingham Study who underwent routine echocardiography. The prevalence of ALVD (visually estimated ejection fraction [EF]<or=50% without a history of CHF) was 6.0% in men and 0.8% in women. During up to 12 years of follow-up, rates of CHF among subjects with normal left ventricular systolic function (EF >50%, n=4128) and ALVD (n=129) were 0.7 and 5.8 per 100 person-years, respectively. After adjustment for cardiovascular disease risk factors, ALVD was associated with a hazards ratio (HR) for CHF of 4.7 (95% CI 2.7 to 8.1), compared with individuals without ALVD. An elevated risk of CHF after ALVD was observed even in individuals without prior myocardial infarction or valvular disease, with an adjusted HR of 6.5 (CI 3.1 to 13.5). Mild ALVD (EF 40% to 50%, n=78) and moderate-to-severe ALVD (EF <40%, n=51) were associated with adjusted HRs for CHF of 3.3 (CI 1.7 to 6.6) and 7.8 (CI 3.9 to 15.6), respectively. ALVD was also associated with an increased mortality risk (adjusted HR 1.6, CI 1.1 to 2.4). The median survival of ALVD subjects was 7.1 years. CONCLUSIONS: Individuals with ALVD in the community are at high risk of CHF and death, even when only mild impairment of EF is present. Additional studies are needed to define optimal therapy for mild ALVD.
BACKGROUND: Information is limited regarding the rates of progression to congestive heart failure (CHF) and death in individuals with asymptomatic left ventricular systolic dysfunction (ALVD). We sought to characterize the natural history of ALVD, by studying unselected individuals with this condition in the community. METHODS AND RESULTS: We studied 4257 participants (1860 men) from the Framingham Study who underwent routine echocardiography. The prevalence of ALVD (visually estimated ejection fraction [EF]<or=50% without a history of CHF) was 6.0% in men and 0.8% in women. During up to 12 years of follow-up, rates of CHF among subjects with normal left ventricular systolic function (EF >50%, n=4128) and ALVD (n=129) were 0.7 and 5.8 per 100 person-years, respectively. After adjustment for cardiovascular disease risk factors, ALVD was associated with a hazards ratio (HR) for CHF of 4.7 (95% CI 2.7 to 8.1), compared with individuals without ALVD. An elevated risk of CHF after ALVD was observed even in individuals without prior myocardial infarction or valvular disease, with an adjusted HR of 6.5 (CI 3.1 to 13.5). Mild ALVD (EF 40% to 50%, n=78) and moderate-to-severe ALVD (EF <40%, n=51) were associated with adjusted HRs for CHF of 3.3 (CI 1.7 to 6.6) and 7.8 (CI 3.9 to 15.6), respectively. ALVD was also associated with an increased mortality risk (adjusted HR 1.6, CI 1.1 to 2.4). The median survival of ALVD subjects was 7.1 years. CONCLUSIONS: Individuals with ALVD in the community are at high risk of CHF and death, even when only mild impairment of EF is present. Additional studies are needed to define optimal therapy for mild ALVD.
Authors: Christopher R deFilippi; Robert H Christenson; Willem J Kop; John S Gottdiener; Min Zhan; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Sachin Gupta; Susan A Matulevicius; Colby R Ayers; Jarett D Berry; Parag C Patel; David W Markham; Benjamin D Levine; Kelly M Chin; James A de Lemos; Ronald M Peshock; Mark H Drazner Journal: Eur Heart J Date: 2012-07-10 Impact factor: 29.983
Authors: S Szmit; M Jank; H Maciejewski; M Grabowski; R Glowczynska; A Majewska; K J Filipiak; T Motyl; G Opolski Journal: J Appl Genet Date: 2010 Impact factor: 3.240
Authors: J Gustav Smith; Christopher Newton-Cheh; Peter Almgren; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Pyotr G Platonov; Bo Hedblad; Gunnar Engström; Thomas J Wang; Olle Melander Journal: J Am Coll Cardiol Date: 2010-11-16 Impact factor: 24.094
Authors: Chau T Dang; Anthony F Yu; Lee W Jones; Jennifer Liu; Richard M Steingart; Daniel F Argolo; Larry Norton; Clifford A Hudis Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544